Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.
2.

Role of co-expressed APOBEC3F and APOBEC3G in inducing HIV-1 drug resistance.

Mohammadzadeh N, Love RP, Gibson R, Arts EJ, Poon AFY, Chelico L.

Heliyon. 2019 Apr 16;5(4):e01498. doi: 10.1016/j.heliyon.2019.e01498. eCollection 2019 Apr.

3.

First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda.

Poon AFY, Ndashimye E, Avino M, Gibson R, Kityo C, Kyeyune F, Nankya I, Quiñones-Mateu ME, Arts EJ; The Ugandan Drug Resistance Study Team.

AIDS Res Ther. 2019 Jan 22;16(1):3. doi: 10.1186/s12981-019-0218-2.

4.

Evolution-Guided Structural and Functional Analyses of the HERC Family Reveal an Ancient Marine Origin and Determinants of Antiviral Activity.

Paparisto E, Woods MW, Coleman MD, Moghadasi SA, Kochar DS, Tom SK, Kohio HP, Gibson RM, Rohringer TJ, Hunt NR, Di Gravio EJ, Zhang JY, Tian M, Gao Y, Arts EJ, Barr SD.

J Virol. 2018 Jun 13;92(13). pii: e00528-18. doi: 10.1128/JVI.00528-18. Print 2018 Jul 1.

5.

A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system.

Pankrac J, Klein K, McKay PF, King DFL, Bain K, Knapp J, Biru T, Wijewardhana CN, Pawa R, Canaday DH, Gao Y, Fidler S, Shattock RJ, Arts EJ, Mann JFS.

NPJ Vaccines. 2018 Jan 19;3:2. doi: 10.1038/s41541-017-0040-6. eCollection 2018.

6.

Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.

Ndashimye E, Avino M, Kyeyune F, Nankya I, Gibson RM, Nabulime E, Poon AFY, Kityo C, Mugyenyi P, Quiñones-Mateu ME, Arts EJ.

AIDS Res Hum Retroviruses. 2018 May;34(5):404-414. doi: 10.1089/AID.2017.0205. Epub 2018 Feb 26.

7.

Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection.

Klein K, Nickel G, Nankya I, Kyeyune F, Demers K, Ndashimye E, Kwok C, Chen PL, Rwambuya S, Poon A, Munjoma M, Chipato T, Byamugisha J, Mugyenyi P, Salata RA, Morrison CS, Arts EJ.

PLoS Pathog. 2018 Jan 18;14(1):e1006754. doi: 10.1371/journal.ppat.1006754. eCollection 2018 Jan.

8.

Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries.

Gibson RM, Nickel G, Crawford M, Kyeyune F, Venner C, Nankya I, Nabulime E, Ndashimye E, Poon AFY, Salata RA, Kityo C, Mugyenyi P, Quiñones-Mateu ME, Arts EJ.

Infect Dis Poverty. 2017 Dec 4;6(1):163. doi: 10.1186/s40249-017-0377-0.

9.

Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses.

Racine T, Kobinger GP, Arts EJ.

AIDS Res Ther. 2017 Sep 12;14(1):55. doi: 10.1186/s12981-017-0179-2. Review.

10.

Postnatal Identification of Zika Virus Peptides from Saliva.

Zuanazzi D, Arts EJ, Jorge PK, Mulyar Y, Gibson R, Xiao Y, Bringel Dos Santos M, Machado MAAM, Siqueira WL.

J Dent Res. 2017 Sep;96(10):1078-1084. doi: 10.1177/0022034517723325.

PMID:
28825520
11.

Tribute to Mark Wainberg.

Arts EJ, Gatignol A, Mouland AJ, Liang C, Götte M, Soudeyns H.

Retrovirology. 2017 Jun 28;14(1):38. doi: 10.1186/s12977-017-0361-6. No abstract available.

12.

Dr. Mark A. Wainberg (1945-2017): Provocateur, Activist, and Champion for AIDS Care and Research.

Arts EJ.

AIDS Res Hum Retroviruses. 2017 May;33(5):iii-iv. doi: 10.1089/aid.2017.29002.art. No abstract available.

PMID:
28475374
13.

An in vitro Model to Mimic Selection of Replication-Competent HIV-1 Intersubtype Recombination in Dual or Superinfected Patients.

Bagaya BS, Tian M, Nickel GC, Vega JF, Li Y, He P, Klein K, Mann JFS, Jiang W, Arts EJ, Gao Y.

J Mol Biol. 2017 Jul 7;429(14):2246-2264. doi: 10.1016/j.jmb.2017.04.016. Epub 2017 May 1.

14.

Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections.

Krebs KC, Tian M, Asmal M, Ling B, Nelson K, Henry K, Gibson R, Li Y, Han W, Shattock RJ, Veazey RS, Letvin N, Arts EJ, Gao Y.

AIDS Res Ther. 2016 Nov 25;13(1):41. doi: 10.1186/s12981-016-0125-8.

15.

First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.

Choi E, Michalski CJ, Choo SH, Kim GN, Banasikowska E, Lee S, Wu K, An HY, Mills A, Schneider S, Bredeek UF, Coulston DR, Ding S, Finzi A, Tian M, Klein K, Arts EJ, Mann JF, Gao Y, Kang CY.

Retrovirology. 2016 Nov 28;13(1):82.

16.

A Highly Conserved Residue in HIV-1 Nef Alpha Helix 2 Modulates Protein Expression.

Johnson AL, Dirk BS, Coutu M, Haeryfar SM, Arts EJ, Finzi A, Dikeakos JD.

mSphere. 2016 Nov 9;1(6). pii: e00288-16. eCollection 2016 Nov-Dec.

17.

Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa.

Venner CM, Nankya I, Kyeyune F, Demers K, Kwok C, Chen PL, Rwambuya S, Munjoma M, Chipato T, Byamugisha J, Van Der Pol B, Mugyenyi P, Salata RA, Morrison CS, Arts EJ.

EBioMedicine. 2016 Nov;13:305-314. doi: 10.1016/j.ebiom.2016.10.014. Epub 2016 Oct 12.

18.

Pathogenic infection of Rhesus macaques by an evolving SIV-HIV derived from CCR5-using envelope genes of acute HIV-1 infections.

Asmal M, Lane S, Tian M, Nickel G, Venner C, Dirk B, Dikeakos J, Luedemann C, Mach L, Balachandran H, Buzby A, Rao S, Letvin N, Gao Y, Arts EJ.

Virology. 2016 Dec;499:298-312. doi: 10.1016/j.virol.2016.09.021. Epub 2016 Oct 7.

19.

Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.

Kyeyune F, Gibson RM, Nankya I, Venner C, Metha S, Akao J, Ndashimye E, Kityo CM, Salata RA, Mugyenyi P, Arts EJ, Quiñones-Mateu ME.

Antimicrob Agents Chemother. 2016 May 23;60(6):3380-97. doi: 10.1128/AAC.00038-16. Print 2016 Jun.

20.

HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.

Tebit DM, Patel H, Ratcliff A, Alessandri E, Liu J, Carpenter C, Plantier JC, Arts EJ.

AIDS Res Hum Retroviruses. 2016 Jul;32(7):676-88. doi: 10.1089/AID.2015.0318. Epub 2016 Mar 16.

21.

Defining the fitness of HIV-1 isolates with dual/mixed co-receptor usage.

Nankya IL, Tebit DM, Abraha A, Kyeyune F, Gibson R, Jegede O, Nickel G, Arts EJ.

AIDS Res Ther. 2015 Oct 3;12:34. doi: 10.1186/s12981-015-0066-7. eCollection 2015.

22.

Functional bottlenecks for generation of HIV-1 intersubtype Env recombinants.

Bagaya BS, Vega JF, Tian M, Nickel GC, Li Y, Krebs KC, Arts EJ, Gao Y.

Retrovirology. 2015 May 23;12:44. doi: 10.1186/s12977-015-0170-8.

23.

SiRNA-induced mutation in HIV-1 polypurine tract region and its influence on viral fitness.

Rausch JW, Tian M, Li Y, Angelova L, Bagaya BS, Krebs KC, Qian F, Zhu C, Arts EJ, Le Grice SF, Gao Y.

PLoS One. 2015 Apr 10;10(4):e0122953. doi: 10.1371/journal.pone.0122953. eCollection 2015.

24.

Similar replicative fitness is shared by the subtype B and unique BF recombinant HIV-1 isolates that dominate the epidemic in Argentina.

Rubio AE, Abraha A, Carpenter CA, Troyer RM, Reyes-Rodríguez ÁL, Salomon H, Arts EJ, Tebit DM.

PLoS One. 2014 Apr 11;9(4):e92084. doi: 10.1371/journal.pone.0092084. eCollection 2014.

25.

Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds.

Liu Y, Rao U, McClure J, Konopa P, Manocheewa S, Kim M, Chen L, Troyer RM, Tebit DM, Holte S, Arts EJ, Mullins JI.

PLoS One. 2014 Apr 8;9(4):e94240. doi: 10.1371/journal.pone.0094240. eCollection 2014.

26.

Differences in Clinical Manifestations of Acute and Early HIV-1 Infection between HIV-1 Subtypes in African Women.

Lemonovich TL, Watkins RR, Morrison CS, Kwok C, Chipato T, Musoke R, Arts EJ, Nankya I, Salata RA.

J Int Assoc Provid AIDS Care. 2015 Sep-Oct;14(5):415-22. doi: 10.1177/2325957413504827. Epub 2013 Oct 8.

27.

Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.

Lobritz MA, Ratcliff AN, Marozsan AJ, Dudley DM, Tilton JC, Arts EJ.

Antimicrob Agents Chemother. 2013 Jun;57(6):2640-50. doi: 10.1128/AAC.02511-12. Epub 2013 Mar 25.

28.

Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.

Weber J, Vazquez AC, Winner D, Gibson RM, Rhea AM, Rose JD, Wylie D, Henry K, Wright A, King K, Archer J, Poveda E, Soriano V, Robertson DL, Olivo PD, Arts EJ, Quiñones-Mateu ME.

J Clin Microbiol. 2013 May;51(5):1517-27. doi: 10.1128/JCM.00092-13. Epub 2013 Mar 13.

29.

A cis-acting element in retroviral genomic RNA links Gag-Pol ribosomal frameshifting to selective viral RNA encapsidation.

Chamanian M, Purzycka KJ, Wille PT, Ha JS, McDonald D, Gao Y, Le Grice SF, Arts EJ.

Cell Host Microbe. 2013 Feb 13;13(2):181-92. doi: 10.1016/j.chom.2013.01.007.

30.

Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism.

Archer J, Weber J, Henry K, Winner D, Gibson R, Lee L, Paxinos E, Arts EJ, Robertson DL, Mimms L, Quiñones-Mateu ME.

PLoS One. 2012;7(11):e49602. doi: 10.1371/journal.pone.0049602. Epub 2012 Nov 14.

31.

Mucosal tissue tropism and dissemination of HIV-1 subtype B acute envelope-expressing chimeric virus.

King DF, Siddiqui AA, Buffa V, Fischetti L, Gao Y, Stieh D, McKay PF, Rogers P, Ochsenbauer C, Kappes JC, Arts EJ, Shattock RJ.

J Virol. 2013 Jan;87(2):890-9. doi: 10.1128/JVI.02216-12. Epub 2012 Nov 7.

32.

HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.

Ratcliff AN, Shi W, Arts EJ.

J Virol. 2013 Jan;87(2):923-34. doi: 10.1128/JVI.01863-12. Epub 2012 Nov 7.

34.

A hybrid stochastic-deterministic computational model accurately describes spatial dynamics and virus diffusion in HIV-1 growth competition assay.

Immonen T, Gibson R, Leitner T, Miller MA, Arts EJ, Somersalo E, Calvetti D.

J Theor Biol. 2012 Nov 7;312:120-32. doi: 10.1016/j.jtbi.2012.07.005. Epub 2012 Jul 17.

PMID:
22814476
35.

HIV-1 antiretroviral drug therapy.

Arts EJ, Hazuda DJ.

Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161. doi: 10.1101/cshperspect.a007161. Review.

36.

Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility.

Santos AF, Tebit DM, Lalonde MS, Abecasis AB, Ratcliff A, Camacho RJ, Diaz RS, Herchenröder O, Soares MA, Arts EJ.

Antimicrob Agents Chemother. 2012 May;56(5):2719-25. doi: 10.1128/AAC.06079-11. Epub 2012 Feb 13.

37.

Past, present, and future of entry inhibitors as HIV microbicides.

Gibson RM, Arts EJ.

Curr HIV Res. 2012 Jan 1;10(1):19-26. Review.

PMID:
22264042
38.

Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.

Weber J, Vazquez AC, Winner D, Rose JD, Wylie D, Rhea AM, Henry K, Pappas J, Wright A, Mohamed N, Gibson R, Rodriguez B, Soriano V, King K, Arts EJ, Olivo PD, Quiñones-Mateu ME.

Antimicrob Agents Chemother. 2011 Aug;55(8):3729-42. doi: 10.1128/AAC.00396-11. Epub 2011 May 31.

39.

Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA.

Lalonde MS, Lobritz MA, Ratcliff A, Chamanian M, Athanassiou Z, Tyagi M, Wong J, Robinson JA, Karn J, Varani G, Arts EJ.

PLoS Pathog. 2011 May;7(5):e1002038. doi: 10.1371/journal.ppat.1002038. Epub 2011 May 19.

40.

HIV-1 replicative fitness in elite controllers.

Lobritz MA, Lassen KG, Arts EJ.

Curr Opin HIV AIDS. 2011 May;6(3):214-20. doi: 10.1097/COH.0b013e3283454cf5. Review.

41.

Enrichment of intersubtype HIV-1 recombinants in a dual infection system using HIV-1 strain-specific siRNAs.

Gao Y, Abreha M, Nelson KN, Baird H, Dudley DM, Abraha A, Arts EJ.

Retrovirology. 2011 Jan 13;8(1):5. doi: 10.1186/1742-4690-8-5.

42.

Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease.

Tebit DM, Arts EJ.

Lancet Infect Dis. 2011 Jan;11(1):45-56. doi: 10.1016/S1473-3099(10)70186-9. Epub 2010 Dec 2. Review.

PMID:
21126914
43.

DNA suspension arrays: silencing discrete artifacts for high-sensitivity applications.

Lalonde MS, Arts EJ.

PLoS One. 2010 Nov 8;5(11):e15476. doi: 10.1371/journal.pone.0015476.

44.

Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors.

Tebit DM, Lobritz M, Lalonde M, Immonen T, Singh K, Sarafianos S, Herchenröder O, Kräusslich HG, Arts EJ.

J Virol. 2010 Oct;84(19):9817-30. doi: 10.1128/JVI.00991-10. Epub 2010 Jul 14.

45.

HIV-1 Entry, Inhibitors, and Resistance.

Lobritz MA, Ratcliff AN, Arts EJ.

Viruses. 2010 May;2(5):1069-105. doi: 10.3390/v2051069. Epub 2010 Apr 29.

46.

Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage.

Soares EA, Santos AF, Gonzalez LM, Lalonde MS, Tebit DM, Tanuri A, Arts EJ, Soares MA.

J Antimicrob Chemother. 2009 Nov;64(5):938-44. doi: 10.1093/jac/dkp315. Epub 2009 Aug 26.

47.

A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains.

Johnston SH, Lobritz MA, Nguyen S, Lassen K, Delair S, Posta F, Bryson YJ, Arts EJ, Chou T, Lee B.

J Virol. 2009 Nov;83(21):11016-26. doi: 10.1128/JVI.01242-09. Epub 2009 Aug 19.

48.

A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates.

Dudley DM, Gao Y, Nelson KN, Henry KR, Nankya I, Gibson RM, Arts EJ.

Biotechniques. 2009 May;46(6):458-67. doi: 10.2144/000113119.

49.

Viral fitness implications of variation within an immunodominant CD8+ T-cell epitope of HIV-1.

Christie NM, Willer DO, Lobritz MA, Chan JK, Arts EJ, Ostrowski MA, Cochrane A, Luscher MA, MacDonald KS.

Virology. 2009 May 25;388(1):137-46. doi: 10.1016/j.virol.2009.03.003. Epub 2009 Apr 15.

50.

Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics.

Lassen KG, Lobritz MA, Bailey JR, Johnston S, Nguyen S, Lee B, Chou T, Siliciano RF, Markowitz M, Arts EJ.

PLoS Pathog. 2009 Apr;5(4):e1000377. doi: 10.1371/journal.ppat.1000377. Epub 2009 Apr 10.

Supplemental Content

Support Center